| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Michael G Ison | |
| P2860 | cites work | Safety and efficacy of peramivir for influenza treatment | Q27027408 |
| Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009 | Q28260987 | ||
| Critically Ill patients with 2009 influenza A(H1N1) in Mexico | Q28261205 | ||
| Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers | Q28272841 | ||
| Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial | Q28359768 | ||
| Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza | Q28473860 | ||
| The annual impact of seasonal influenza in the US: Measuring disease burden and costs | Q29030744 | ||
| Origins and evolution of antibiotic resistance | Q29617791 | ||
| Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. | Q30306435 | ||
| Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. | Q30356962 | ||
| Pregnancy outcome following maternal use of zanamivir or oseltamivir during the 2009 influenza A/H1N1 pandemic: a national prospective surveillance study. | Q30359847 | ||
| Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings pre- and post-2009 H1N1 pandemic. | Q30360221 | ||
| Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. | Q30362392 | ||
| Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. | Q30382272 | ||
| Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women | Q30387165 | ||
| Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States | Q30388312 | ||
| Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study | Q30391256 | ||
| Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant | Q30391390 | ||
| Safety of oseltamivir in pregnancy: a review of preclinical and clinical data | Q30391483 | ||
| Pandemic influenza A (H1N1) in pregnant women: impact of early diagnosis and antiviral treatment | Q30393341 | ||
| Pharmacokinetic properties of anti-influenza neuraminidase inhibitors | Q38084212 | ||
| Use of Oseltamivir to control influenza complications after bone marrow transplantation | Q39199981 | ||
| Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis | Q39428892 | ||
| Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. | Q39430012 | ||
| Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study | Q39431184 | ||
| Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial | Q40152886 | ||
| Early administration of oral oseltamivir increases the benefits of influenza treatment | Q40568853 | ||
| Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group | Q40625504 | ||
| Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers | Q42110576 | ||
| Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. | Q42204936 | ||
| Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958. | Q42651351 | ||
| Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical Trial | Q42862553 | ||
| Outcomes of adults hospitalised with severe influenza. | Q43044944 | ||
| Characteristics of pregnant Japanese women who required hospitalization for treatment of pandemic (H1N1) 2009--low mortality rate may be due to early antiviral use. | Q43173313 | ||
| Fatal respiratory events caused by zanamivir nebulization | Q43185904 | ||
| Strengthening observational evidence for antiviral effectiveness in influenza A (H5N1). | Q43572962 | ||
| Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity | Q43812035 | ||
| Editorial commentary. "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never? | Q43865089 | ||
| Viral loads and duration of viral shedding in adult patients hospitalized with influenza. | Q43873120 | ||
| Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers | Q44153168 | ||
| Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers | Q44779710 | ||
| Health outcomes among patients receiving oseltamivir. | Q44979353 | ||
| Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. | Q45974600 | ||
| Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. | Q46142983 | ||
| Outcome of influenza infection managed with oseltamivir in lung transplant recipients | Q46700589 | ||
| Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America | Q48585293 | ||
| Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. | Q48719424 | ||
| Critically ill patients with 2009 influenza A(H1N1) infection in Canada. | Q50580869 | ||
| French experience of 2009 A/H1N1v influenza in pregnant women | Q30395018 | ||
| Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza | Q30396669 | ||
| The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients | Q30399407 | ||
| Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009. | Q30400029 | ||
| Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients | Q30402383 | ||
| Complications and outcomes of pandemic 2009 Influenza A (H1N1) virus infection in hospitalized adults: how do they differ from those in seasonal influenza? | Q30403081 | ||
| Risk factors for severe outcomes following 2009 influenza A (H1N1) infection: a global pooled analysis | Q30404745 | ||
| Description of antiviral treatment among adults hospitalized with influenza before and during the 2009 pandemic: United States, 2005-2009. | Q30408429 | ||
| Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients | Q30410097 | ||
| Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives | Q30410899 | ||
| Diagnosis, management and outcomes of adults hospitalized with influenza | Q30412653 | ||
| Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic | Q30416134 | ||
| A large, population-based study of 2009 pandemic Influenza A virus subtype H1N1 infection diagnosis during pregnancy and outcomes for mothers and neonates | Q30420010 | ||
| Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients | Q30424329 | ||
| Clinical use of approved influenza antivirals: therapy and prophylaxis | Q30425343 | ||
| Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group. | Q30471016 | ||
| BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design | Q31440495 | ||
| Oral oseltamivir treatment of influenza in children. | Q32064242 | ||
| Clinical findings in 111 cases of influenza A (H7N9) virus infection | Q33407904 | ||
| The influence of oseltamivir treatment on the risk of stroke after influenza infection | Q33621263 | ||
| Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection | Q33876428 | ||
| Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. | Q34217769 | ||
| Influenza virus neuraminidase: structure, antibodies, and inhibitors | Q34318113 | ||
| Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season | Q34354261 | ||
| Neuraminidase inhibitors for influenza | Q34455162 | ||
| Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem | Q34514304 | ||
| Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients | Q35005030 | ||
| Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials | Q35097867 | ||
| Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. | Q35906893 | ||
| Annual economic impacts of seasonal influenza on US counties: spatial heterogeneity and patterns | Q36341234 | ||
| Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada | Q37055208 | ||
| Pharmacokinetics of high-dose oseltamivir in healthy volunteers | Q37115683 | ||
| Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women | Q37247004 | ||
| Antivirals and resistance: influenza virus | Q37996227 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 417-425 | |
| P577 | publication date | 2015-02-19 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Optimizing antiviral therapy for influenza: understanding the evidence | |
| P478 | volume | 13 |
| Q45325322 | A pharmacologically immunosuppressed mouse model for assessing influenza B virus pathogenicity and oseltamivir treatment |
| Q40640818 | Antiviral Effects of Black Raspberry (Rubus coreanus) Seed and Its Gallic Acid against Influenza Virus Infection |
| Q64900534 | Competitive Cooperation of Hemagglutinin and Neuraminidase during Influenza A Virus Entry. |
| Q61807074 | Influenza Virus Neuraminidase Structure and Functions |
| Q41123104 | Oseltamivir inhibits influenza virus replication and transmission following ocular-only aerosol inoculation of ferrets |
| Q28068310 | Peramivir injection in the treatment of acute influenza: a review of the literature |
| Q46493128 | Pneumonia in the tropics: Report from the Task Force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine |
| Q42629986 | Soloxolone methyl inhibits influenza virus replication and reduces virus-induced lung inflammation |
| Q57009788 | The Cranberry Extract Oximacro Exerts Virucidal Activity Against Influenza Virus by Interfering With Hemagglutinin |
Search more.